Cosentyx is a medication used to treat certain autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It contains the active ingredient secukinumab, which works by blocking a specific protein in the body that is involved in the inflammatory response.

Regarding the safety of Cosentyx for elderly individuals, the available sources provide some insights. However, it is important to note that the information provided here is based solely on the provided sources and should not replace professional medical advice. It is crucial for elderly patients to consult with their healthcare provider before starting or changing any medication.

According to the first source, Drug Patent Watch, there is no specific information available regarding the safety of Cosentyx for elderly patients. The source primarily provides information about the patent status of the drug and does not delve into specific safety concerns for different age groups.

The second source, a study published in the journal "Expert Opinion on Biological Therapy," discusses the safety and efficacy of secukinumab (the active ingredient in Cosentyx) in the treatment of psoriasis in elderly patients. The study suggests that secukinumab can be considered a safe and effective treatment option for elderly patients with psoriasis. However, it is important to note that this study specifically focuses on psoriasis and does not provide information on the safety of Cosentyx for other conditions or in elderly patients with other comorbidities.

The third source, a study published in the journal "Therapeutic Advances in Musculoskeletal Disease," discusses the use of secukinumab in elderly patients with psoriatic arthritis and ankylosing spondylitis. The study suggests that secukinumab is generally well-tolerated in elderly patients with these conditions, with a safety profile similar to that observed in younger patients. However, the study also highlights the importance of individualized treatment decisions, taking into account factors such as comorbidities and concomitant medications.

In conclusion, while the available sources provide some insights into the safety of Cosentyx in elderly patients, it is important to note that the information is limited and specific to certain conditions. It is crucial for elderly individuals to consult with their healthcare provider to assess the potential risks and benefits of using Cosentyx, taking into consideration their individual medical history and any other medications they may be taking.

Sources:
[1] Drug Patent Watch - https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Expert Opinion on Biological Therapy - https://pubmed.ncbi.nlm.nih.gov/29404966/
[3] Therapeutic Advances in Musculoskeletal Disease - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847154/